68-5

78/120

528pathic pulmonary fibrosis: a randomised trial. Eur Respir J, 2020: 2000348. 19) Kobayashi K, Soejima K, Fukunaga K, Shin‑tani Y, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Takahashi K, Yamamoto N, Takiguchi Y, Miyaoka E, Okumura M, Yoshino I, and on behalf of the Group on behalf of the Japanese Joint Committee of Lung Cancer Registry: Key prognostic factors for EGFR-mutated non- adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database. Lung Cancer, 2020; 146: 236-243. 20) Igawa S, Naoki K, Shintani Y, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Takahashi K, Yamamoto N, Taki‑guchi Y, Miyaoka E, Okumura M, Yoshino I: Survival and Prognostic Factors in Elderly Patients Receiving Second-line Chemotherapy for Relapsed Small-Cell Lung Cancer: Results from the Japanese Joint Committee of Lung Cancer Registry. Lung Cancer, 2020; 146: 160-164. 21) Harada N, Harada S, Ito J, Atsuta R, Hori S, Takahashi K: Mobile Health App for Japa‑nese Adult Patients With Asthma: Clinical Observational Study. J Med Internet Res, 2020; 22: e19006. 22) Tanaka K, Morita S, Ando M, Yokoyama T, Nakamura A, Yoshioka H, Ishiguro T, Miura S, Toyozawa R, Oguri T, Daga H, Ko R, Bessho A, Tashihara M, Iwamoto Y, Hirano K, Nakanishi Y, Nakagawa K, Yamamoto N, Okamoto I: A randomized phase 3 study of maintenance therapy with S-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L). Cancer, 2020; 125: 3648-3656. 23) Tsuboshima K, Kurihara M, Yamanaka T, Watanabe K, Matoba Y, Seyama K: Does a gender have something to do with clinical pictures of primary spontaneous pneumo‑thorax？ Gen Thorac Cardiovasc Surg, 2020; 68: 741-745. 24) Yamauchi M, Nakayama H, Shiota S, Ohshima Y, Terada J, Nishijima T, Kosuga M, Kitamura T, Tachibana N, Oguri T, Shirahama R, Aoki Y, Ishigaki K, Sugie K, Yagi T, Muraki H, Fujita Y, Takatani T, Muro S: Potential patient screening for late-onset Pompe disease in suspected sleep apnea: a rationale and study design for a Prospective Multicenter Obser‑vational Cohort Study in Japan (PSSAP-J Study). Sleep Breath, 2020. doi: 10.1007/s11325-020-02170-6. Online ahead of print. 25) Wang K, Verbakel JY, Oke J, Fleming-Nouri A, Harada N, Atsuta R, Fujisawa T, Kawayama T, Inoue H, Lazarus S, Szefler S, Martinez FD, Shaw D, Pavord ID, Thomas M: Using fractional exhaled nitric oxide to guide step-down treatment decisions in asthma: prac‑tical considerations. Eur Respir J, 2020; 56: 2002809. 26) Miyawaki T, Kenmotsu H, Mori K, Miyawaki E, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Harada H, Endo M, Ohde Y, Takahashi K, Takahashi T: Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer, 2020; 21: e405-e414. 27) Hayashi T, Kohsaka S, Takamochi K, Hara K, Kishikawa S, Sano K, Takahashi F, Suehara Y, Saito T, Takahashi K, Suzuki K, Yao T: Clinicopathological characteristics of lung adenocarcinoma with compound EGFR muta‑tions. Hum Pathol, 2020; 103: 42-51. 28) Kato Y, Kato M, Ihara H, Hayakawa E, Shibayama K, Miura K, Yamada T, Mitsuishi Y, Shukuya T, Ito J, Matsunaga T, Sato T, Suzuki K, Takahashi K: Hermansky-Pudlak syndrome-associated pneumothorax with rapid progression of respiratory failure: a case report. BMC Pulm Med, 2020; 20: 259. 29) Kishikawa S, Hayashi T, Saito T, Takamochi K, Kohsaka S, Sano K, Sasahara N, Sasa K, Kurihara T, Hara K, Suehara Y, Takahashi F, Suzuki K, Yao T: Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarci‑noma. Modern Pathology, 2020; doi: 10.1038/s41379-020-00690-w. Online ahead of print. 30) Takei S, Ihara H, Togo S, Nakamura A, Fujimoto Y, Watanabe J, Kurokawa K,